Malignant Mesothelioma Pathogenesis, Diagnosis, and Translational Therapies [Hardcover]

Malignant Mesothelioma brings together the most current diagnostic criteria and treatment plans from the worlds leading experts on this rare but devastating cancer. The first edition was a critical and commercial success and this revision builds on that reputation. The editors have brought together the worlds leading experts to fully explore the latest scientific breakthroughs in carcinogenesis, immunotherapy, potential vaccination strategies, and gene therapy. The clinical aspects of the book are equally strong, with thorough discussion of epidemiology, etiology, different clinical presentations, imaging (including interventional pulmonology), treatment of benign disease, strategies for multimodality treatment of malignant disease.

Editors: Harvey I. Pass, M.D, Chief, Thoracic Surgery, New York University, New York, NY; Nicholas Vogelzang, M.D, Director, Nevada Cancer Institute, Las Vegas, NV; University of Chicago, Michele Carbone, M.D., Ph.D, Researcher and Director, Thoracic Oncology Program, Cancer Research Center of Hawaii, Honolulu, HI; and Anne S. Tsao, M.D, Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

(Review from JAMA)

Malignant mesothelioma is an uncommon neoplasm usually associated with exposure to asbestos. Because of its low incidence, thorough reviews of the topic are hard to find.

Harvey Pass and colleagues have edited an up-to-date, comprehensive book that includes a wide range of information, from a historical perspective to descriptions of the latest treatment. The authors . . . have written chapters on the carcinogenesis, molecular genetics, and clinical aspects of mesothelioma. Malignant Mesothelioma is suitable for a broad audience. Laboratory researchers will use it as a resource for information about the pathogenesis, animal models, molecularló4